An Josiah, Garje Rohan, Wanat Karolyn A, Leone José Pablo
Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
BMJ Case Rep. 2017 Jan 4;2017:bcr2016217423. doi: 10.1136/bcr-2016-217423.
Dabigatran is a non-vitamin K antagonist oral anticoagulant that has been approved for atrial fibrillation and prevention of venous thromboembolism. Its use has been increasing in the USA since serum drug levels do not need monitoring. To date, no significant skin side effects have been reported other than 4 cases of non-specific skin lesion and 2 cases of leukocytoclastic vasculitis (LCV), which is a small vessel inflammatory disease that presents as palpable purpura in lower extremities. We present a man aged 57 years with chronic deep vein thrombosis who developed palpable purpura, petechiae, swelling in lower extremities, torso and distal upper extremities on the third day after dabigatran initiation. The present case highlights the potential risk for LCV with dabigatran use and provides insight into its management.
达比加群是一种非维生素K拮抗剂口服抗凝药,已被批准用于房颤和预防静脉血栓栓塞。自血清药物水平无需监测以来,其在美国的使用一直在增加。迄今为止,除了4例非特异性皮肤病变和2例白细胞破碎性血管炎(LCV)外,尚未报告有明显的皮肤副作用,LCV是一种小血管炎性疾病,表现为下肢可触及的紫癜。我们报告一例57岁患有慢性深静脉血栓形成(DVT)的男性患者,在开始使用达比加群第三天出现了可触及的紫癜、瘀点、下肢、躯干和上肢远端肿胀。本病例突出了使用达比加群发生LCV的潜在风险,并为其管理提供了见解。